Postmarketing Hepatic Monitoring for Pazopanib Using Observational Databases
Phase of Trial: Phase IV
Latest Information Update: 11 Jun 2014
At a glance
- Drugs Pazopanib (Primary) ; Bevacizumab; Sorafenib; Sunitinib
- Indications Renal cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 18 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Feb 2013 Planned number of patients changed (1) added as reported by ClinicalTrials.gov record.
- 21 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.